Tumor necrosis factor receptor superfamily member 8 (CD30) and Fc gamma receptor IIIa (CD16A) (CD30/CD16A)

The CD30/CD16A target complex represents a dual-receptor engagement strategy used in immunotherapy, specifically through the bispecific antibody AFM13 (Affimed, 2024). CD30, also known as Tumor necrosis factor receptor superfamily member 8 (TNFRSF8), is a cell surface receptor highly expressed on malignant Reed-Sternberg cells in Hodgkin lymphoma and certain T-cell lymphomas (UniProt P28908). CD16A, or Fc gamma receptor IIIa (FCGR3A), is an activating receptor found on natural killer (NK) cells and macrophages that mediates immune effector functions (UniProt P08637). By bridging these two receptors, therapeutic agents like AFM13 redirect the innate immune system to recognize and eliminate CD30-expressing tumor cells (Reiners et al., 2013). This mechanism bypasses the need for traditional monoclonal antibody Fc-region interactions, potentially enhancing the potency of the immune response against refractory cancers (Sawas et al., 2019). Clinical applications focus primarily on CD30-positive hematologic malignancies where standard treatments have failed (NCT04074746).

Other names

TNFRSF8FCGR3AKi-1 antigenFc gamma receptor III-alphaCD30CD16ACD30/CD16A bispecific target

AFM13 is a bispecific tetravalent antibody (TandAb) that simultaneously binds to CD30 on tumor cells and CD16A on natural killer (NK) cells and macrophages (Affimed, 2024). This dual binding facilitates the recruitment and activation of effector cells, leading to the targeted destruction of CD30-positive malignant cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) (Rothe et al., 2015).